Mayuko Haraikawa 研究室

AI 要約（直近 5 年の研究成果）

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

研究成果（14 件）

• [2025] Hydrogen Gas Inhalation Improved Intestinal Microbiota in Ulcerative Colitis: A Randomised Double-Blind Placebo-Controlled Trial
  DOI: https://doi.org/10.3390/biomedicines13081799
• [2024] Comparison of the Effectiveness of Vedolizumab and Ustekinumab in Patients with Ulcerative Colitis: A Real-World Retrospective Study
  DOI: https://doi.org/10.3390/biomedicines12091991
• [2024] Remission Factors for Ustekinumab Treatment of Ulcerative Colitis: A Multicenter Retrospective Study of Real-World Data in Japan
  DOI: https://doi.org/10.3390/biomedicines12051119
• [2023] Correlation between Constipation Symptoms and Abdominal CT Imaging: A Cross-Sectional Pilot Study
  DOI: https://doi.org/10.3390/jcm12010341
• [2023] Successful Treatment of Steroid-resistant Eosinophilic Gastrointestinal Disease with Mepolizumab
  DOI: https://doi.org/10.2169/internalmedicine.0801-22
• [2023] Enterolith Treated with a Combination of Double-Balloon Endoscopy and Cola Dissolution Therapy
  DOI: https://doi.org/10.3390/medicina59030573
• [2022] Differential diagnosis of ulcerative colitis with increased diarrhea; collagenous colitis or irritable bowel syndrome? A case report
  DOI: https://doi.org/10.1177/03000605221140686
• [2022] S112 Optimal Timing and Donor-Patient Matching of Fecal Microbiota Transplantation for Ulcerative Colitis
  DOI: https://doi.org/10.14309/01.ajg.0000897956.79680.d3
• [2022] Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis
  DOI: https://doi.org/10.3390/biomedicines10102526
• [2022] Efficacy of cytapheresis for induction therapy and extra‐intestinal skin manifestations of ulcerative colitis
  DOI: https://doi.org/10.1111/1744-9987.13823

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。